論文・技術情報追加のお知らせ

1. Ductus Arteriosus Variability Linked to Maternal Drug Exposure: Assessment of the USFDA Adverse Event Reporting System using Disproportionality Analysis.

母体薬物暴露と動脈管異常の関連、安全性強化必要

対象DB：FAERS

2. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil.

抗甲状腺薬の安全性評価、副作用リスク低減支援

対象DB：FAERS

3. Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.

ドルテグラビル安全性評価、長期リスク管理重要

対象DB：FAERS

4. Identification of potential drug-induced neuralgia signals through disproportionality analysis of the FAERS database.

薬剤誘発性神経痛、化学療法薬に重点を置く必要性

対象DB：FAERS

5. Exploring Adverse Event Associations of Predicted PXR Agonists Using the FAERS Database.

PXR活性、薬剤性心血管障害リスクに関与示唆

対象DB：FAERS

6. Pharmacovigilance of five commonly used antibiotics in acute exacerbations of COPD (AECOPD): Analysis of the FDA Adverse Event Reporting System database.

COPD急性増悪時抗生物質、新規副作用を警戒

対象DB：FAERS

7. Safety of antidepressants commonly used in 6-17-year-old children and adolescents: A disproportionality analysis from 2014-2023 on the basis of the FAERS database.

児童・青年向け抗うつ薬、副作用の新たな知見示唆?

対象DB：FAERS

8. Signal mining for non-bleeding adverse event in novel oral anticoagulants: a pharmacovigilance study based on FAERS database.

NOACsの非出血性副作用、多臓器に影響示唆

対象DB：FAERS

9. Recombinant human growth hormone and brain neoplasm association: a pharmacovigilance and Mendelian randomization analysis based on US FAERS, Japanese JADER, and Canadian CVARD.

rhGH使用と脳腫瘍の因果関係が示唆される

対象DB：CVAR,FAERS,JADER

10. Safety evaluation of tucatinib: Adverse event signal mining and analysis based on the FAERS database.

トゥカチニブ、多様な副作用リスクを詳細確認

対象DB：FAERS

11. Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse event reporting system.

PPIはH2RAより多くの癌リスクと関連が示唆

対象DB：FAERS

12. Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database.

パクリシニブ使用で消化器障害など有害事象確認

対象DB：FAERS

13. Assessment of drug-related migraine in a real-world large-scale database.

薬剤誘発性偏頭痛、女性に多くリスク薬特定

対象DB：FAERS

14. Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report.

TPO-RAで血栓リスク確認、男女・年齢で差異

対象DB：FAERS,JADER

15. Analysis of Talimogene Laherparepvec (T-VEC) Safety Signals from Food and Drug Administration Adverse Event Reporting System (FAERS).

腫瘍溶解ウイルスT-VECの安全性評価と年齢関連リスク

対象DB：FAERS

16. Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database.

ICIは心筋炎・心膜炎リスク増大を示唆

対象DB：FAERS

17. Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database.

デウクラバシチニブの市販後安全性評価

対象DB：FAERS

18. Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.

肝癌治療薬トレメリムマブとデュルバルマブ安全性解析

対象DB：FAERS

19. Concomitant use of low molecular weight heparin mitigates bortezomib-induced peripheral Neuropathy: Analysis of the FDA adverse event reporting system.

ボルテゾミブと抗凝固剤併用による末梢神経障害リスク解析

対象DB：FAERS

20. Adverse events associated with mesalazine in the real-world: A comprehensive pharmacovigilance analysis of the FAERS and JADER databases.

メサラジン有害事象の実世界データによる薬剤疫学解析

対象DB：JADER

21. The role of XLIF in spinal revision surgery involving failed interbody implants: a review of technique, outcomes, and indications.

脊椎異物除去におけるXLIFアプローチの有効性と安全性

対象DB：JADER

22. An assessment of anti-VEGF drugs safety based on real-world data: from popularity to spontaneous reporting in eudravigilance database.

加齢黄斑変性治療における抗VEGF薬の有害事象解析

対象DB：EudraVigilance

23. Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden.

スウェーデンにおけるCOVID-19ワクチン接種後死亡事例の解析

対象DB：EudraVigilance

24. Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database.

RWDによるベラタセプトの安全性再評価

対象DB：VigiBase

25. Validation of an algorithm for identifying patients with febrile neutropenia: an epidemiological study using real-world data in Japan.

DPCデータによる日本の発熱性好中球減少症の疫学解析

対象DB：DPC

26. Clinical features and outcomes of peripartum obstetric patients admitted to the intensive care unit: A nationwide inpatient database in Japan.

日本における産科ICU入室患者の全国的臨床解析

対象DB：DPC

27. Patients aged 80 and above face higher critical systemic complication rates after single-stage bilateral versus unilateral total knee arthroplasty: a nationwide database analysis.

80歳以上における片側・両側同時人工膝関節置換術のリスク比較

対象DB：DPC

28. Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in Japan.

日本の小児成長ホルモン治療中断率と持続性解析

対象DB：JMDC,MDV

29. Projected burden of femoral fracture surgeries in Japan through 2035: a nationwide population-based modeling study.

2025-2035日本の大腿骨骨折手術件数の予測分析

対象DB：NDB

30. Japan's Nationwide Trend in Scoliosis Surgery from 2014 to 2022; from a Country with a Declining Underage Population.

日本の未成年人口減少と側弯症手術増加の解析

対象DB：NDB

31. Determining the most frequent combinations of drugs prescribed prior to bullous pemphigoid diagnosis using association rule mining: a UK population-based case-control study.

高齢者の心血管薬併用と水疱性類天疱瘡リスクの関係

対象DB：CPRD

32. How well are marginalised groups represented in electronic records? A codelist development project and cross-sectional analysis of UK electronic health records.

少数民族・障害・疾患の識別用コードリスト最適化研究

対象DB：CPRD

33. Trends in cannabis adverse reaction reports: A descriptive analysis of spontaneous reporting data submitted to the Canada Vigilance Program since legalization and regulation of cannabis for non-medical purposes in Canada.

カナダの合法大麻製品に関する有害反応報告分析

対象DB：CVAR